For legal professionals involved in the pharmaceutical industry, the concept of build-to-buy deals is hardly foreign. This transactional structure is based on the exciting potentials of new therapeutic developments and the high hopes of realizing a return on investment and making a positive change in the lives of patients.
In a recent article by Hogan Lovells, hosted by JD Supra, experts discuss the realities of these ventures, acknowledging that despite the best of intentions and even the most talented research teams, there could come a scenario where a build-to-buy collaboration fails to produce an innovation that the buyer is willing to purchase. The inherent uncertainties in scientific research and clinical trials contribute to this risk in build-to-buy deals.
The advice here is clear: while enthusiasm and passion are essential for these kinds of ventures, they should be balanced with a keen attention to potential risks. This calls for a careful and considered analysis, understanding the landscape for the putative product should the research collaboration not yield successful results. It is essential to pre-determine the spill-over rights if the buyer elects not to exercise its option. The buyer’s rights should either terminate or convert to a passive interest to avoid potential Controlling Person liability.
This balanced approach is not merely prudent business strategy, but also an excellent legal safeguard. It reinforces the importance of strategic anticipation, adroit risk management, and the use of legal expertise in navigating the complexities of high-stake pharmaceutical transactions.
As corporate law professionals, staying informed about such crucial insights and industry-specific guidelines not only broadens our understanding but can provide a substantial advantage in successfully managing risks and ensuring that the best interests of our client organizations are catered for, while providing the best possible service to stakeholders.